FY2029 Earnings Estimate for XENE Issued By Wedbush

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico forecasts that the biopharmaceutical company will earn $5.54 per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

Other research analysts have also recently issued reports about the stock. Raymond James reissued an “outperform” rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $56.00.

Xenon Pharmaceuticals Trading Up 2.0 %

XENE stock opened at $39.98 on Friday. The business’s 50 day moving average price is $40.23 and its two-hundred day moving average price is $40.79. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter in the previous year, the firm earned ($0.73) earnings per share.

Insiders Place Their Bets

In other news, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gary Patou sold 4,891 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the completion of the sale, the director now directly owns 23,573 shares of the company’s stock, valued at $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.52% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC increased its stake in Xenon Pharmaceuticals by 144.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after buying an additional 1,507,135 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Vestal Point Capital LP raised its position in shares of Xenon Pharmaceuticals by 57.1% during the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock valued at $32,480,000 after buying an additional 300,000 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of Xenon Pharmaceuticals by 74.7% during the second quarter. Point72 Asset Management L.P. now owns 482,022 shares of the biopharmaceutical company’s stock worth $18,794,000 after acquiring an additional 206,163 shares during the last quarter. Finally, FMR LLC grew its stake in Xenon Pharmaceuticals by 2.2% during the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after acquiring an additional 149,511 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.